MAP Pharmaceuticals (MAPP) Merger Shareholder Lawsuit
Map Pharmaceuticals (MPSS) merger summary
MAP Pharmaceuticals Inc. has announced its acquisition by Allergan Inc. Under the terms of the merger agreement, MAP Pharmaceuticals shareholders will receive $25 for each share of MAPP stock they own. The transaction has a total approximate value of $958 million.
Map Pharmaceuticals (MPSS) merger disclosure raises questions for MAPP shareholders
Is $25.00 per share fair value for Map Pharmaceuticals shareholders?
Have Map Pharmaceuticals board members complied with all duties owed to MAPP shareholders?
Has the Map Pharmaceuticals board of directors properly shopped the company to all possible suitors?
Map Pharmaceuticals (MPSS) merger shareholder investigation
We are investigating whether the proposed transaction is fair to Map Pharmaceuticals shareholders. The investigation concerns whether the MAPPs board of directors’ process for consideration of the proposed transaction was adequate, whether Map Pharmaceuticals is acting in its shareholders’ best interests and whether the proposed share price to be paid to Map Pharmaceuticals shareholders is fair and adequate. If you own the common stock of Map Pharmaceuticals and if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please fill out the contact form on this web page or call Attorney George Pressly at Morgan & Morgan toll free at 1 (800) 631-6234
MAPP Shareholders: Complete this form for FREE LEGAL REVIEW.